Strasbourg, France – July 14, 2025 — French HealthTech company Dreampath Diagnostics has landed a strategic growth investment from U.S.-based Summit Partners, a move set to accelerate the digital transformation of pathology labs across the globe.
Founded in 2012, Dreampath is rethinking how anatomical pathology laboratories handle one of their most critical tasks — archiving and retrieving tissue samples. While many labs still rely on outdated, manual systems, Dreampath offers an automated, traceable alternative. The company’s closed-loop platform integrates proprietary scanners, software, and consumables to streamline sample management — cutting error rates and improving diagnostic efficiency.
“Pathology labs are essential to patient care, but their processes haven’t evolved with the times,” said Pablo Jordan, CEO and co-founder of Dreampath. “Our goal is to bring precision and speed to these workflows. With Summit’s backing, we’re scaling our technology to help more labs deliver faster and safer diagnostics.”
Though the financial terms remain undisclosed, the investment will fuel Dreampath’s global expansion, product development, and operational scale-up. The company is already managing over 250 million tissue samples across 500+ labs in nearly 40 countries, serving hospitals, cancer centers, research institutions, and commercial labs.
Dreampath’s system boasts over 80 global patents and has delivered measurable results for users — including an 83% reduction in archiving time. As pathology labs face mounting pressure from rising sample volumes and labor shortages, solutions like Dreampath’s are becoming mission-critical.
“Dreampath is tackling a major bottleneck in the pathology workflow,” said Thomas Tarnowski, Managing Director at Summit Partners. “Their tech not only saves time but also reduces risk — a crucial combination for improving patient care.”
Summit Partners’ investment marks Dreampath’s first institutional backing. Alongside the funding, Tarnowski and Jono Pagden, Principal at Summit, will join Dreampath’s board of directors.
“We see Dreampath as a category leader in a market ripe for disruption,” Pagden said. “Their early mover advantage, product quality, and global traction position them perfectly to modernize how labs operate — and ultimately, how patients receive care.”
With a reported CAGR of over 50% in recent years and growing demand across the U.S., EMEA and beyond, Dreampath appears poised to set a new standard in digital pathology infrastructure.
